trial
as of 2026-07-01Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients
NCTId NCT01399450
at a glance
Phase 4 · Completed
Enrollment 11 (actual)
Sponsored by Seoul National University Hospital
Primary completion 2016-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
11 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-08
Primary completion
2016-07
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Seoul National University HospitalLead Sponsor
Johnson & JohnsonCollaborator
Investigators
1
Yong Min Ahn, MD, PhDPrincipal Investigator
Sites
2 total
Goyang-si, South KoreaSeoul, South Korea
Facts & assertions
4 sourced
Enrollment
11
Phase
PHASE4
Primary Completion Date
2016-07
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
company
indication
investigator
person